Influence of Benagene Supplementation in Conjunction with High Intensity Cycling Exercise by Simmons, Wilson P
The University of Southern Mississippi 
The Aquila Digital Community 
Honors Theses Honors College 
Fall 12-2015 
Influence of Benagene Supplementation in Conjunction with High 
Intensity Cycling Exercise 
Wilson P. Simmons 
University of Southern Mississippi 
Follow this and additional works at: https://aquila.usm.edu/honors_theses 
 Part of the Exercise Science Commons 
Recommended Citation 
Simmons, Wilson P., "Influence of Benagene Supplementation in Conjunction with High Intensity Cycling 
Exercise" (2015). Honors Theses. 343. 
https://aquila.usm.edu/honors_theses/343 
This Honors College Thesis is brought to you for free and open access by the Honors College at The Aquila Digital 
Community. It has been accepted for inclusion in Honors Theses by an authorized administrator of The Aquila 
Digital Community. For more information, please contact Joshua.Cromwell@usm.edu. 
  
The University of Southern Mississippi 
 
 
Influence of Benagene Supplementation in Conjunction with High Intensity Cycling 
Exercise 
 
 
by 
 
 
Wilson Powell Simmons 
 
 
A Thesis 
Submitted to the Honors College of  
The University of Southern Mississippi 
in Partial Fulfillment  
of the Requirements for the Degree of  
Bachelor of Science 
in the Department of Biological Sciences 
 
 
 
 
 
 
 
December 2015 
 
  
ii 
 
  
iii 
Approved by 
 
 
 
 
 
 
 
 
 
____________________________________ 
Joseph C. Boyd, Ph.D., Thesis Advisor 
Professor of Exercise Science 
 
 
 
 
 
 
 
 
 
 
____________________________________ 
Scott Piland, Ph.D., Director 
School of Kinesiology 
 
 
 
 
 
 
 
 
 
 
____________________________________ 
Ellen Weinauer, Ph.D., Dean 
Honors College 
  
iv 
Abstract 
 
 High intensity aerobic performance is determined by the body’s maximal 
ability to match lactate production and clearance rates, defined as the lactate threshold 
(LaTh).  Intensities performed above the LaTh result in accumulation of lactate 
causing fatigue.  In a double-blind experiment, using trained cyclists and triathletes, 
we investigated skeletal muscle adaptations that occurred following 28-days of 
Benagene supplementation (oxaloacetate).  The testing protocol consisted of an initial 
cycle test (T1) to measure VO2max, LaTh, respiratory exchange ratio (RER), power 
output (PO) and heart rate (HR).  Testing began after a 15-min warm-up at 75W, 
beginning at 100W, increasing 30W each 3-min stage until subjects could no longer 
maintain within 10 rpms of their self-selected pedal rate.  Within 3-5 days, subjects 
performed the second trial (T2) that consisted of a 15-min warm-up at 100 W, 
followed by a 30-min cycle test to measure power and heart rate at LaTh.  Subjects 
then repeated T1 and T2 within 3-7 days after 28-days of supplementation.  Results 
are inconclusive at this time due to the low subject numbers (3 treatment, 3 control), 
which resulted from high dropout rates.  It was hypothesized that the Benagene 
supplementation may postpone the accumulation of lactate and therefore increase PO 
at LaTh. 
 
 
Key Words: Oxaloacetate, Benagene, Lactate Threshold, Power, VO2, Respiratory 
Exchange Rate, Heart Rate. 
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Chapter 1: Introduction 
 
Metabolism 
 
 There are several key pathways that contribute to metabolic energy 
production.  Aerobic metabolism, processes completed through the presence of 
oxygen, tends to produce the high amounts adenosine triphosphate, ATP, allowing for 
long bouts of exercise.  Aerobic metabolism largely consists of glycolysis, the Kreb’s 
cycle, and oxidative phosphorylation. 
 The aerobic continuation of glycolysis results in the production of pyruvate, a 
widely useful conjugate base to pyruvic acid which can be altered to form many 
useful products in regard to the cell metabolism.  One of these products, acetyl-CoA, 
is a precursor for the Kreb’s cycle, also known as the Citric Acid cycle.  By reducing 
the molecule via the extraction of hydrogen atoms and the addition of the coenzyme-
A group, the conversion of pyruvate to acetyl-CoA allows for effective production of 
ATP in the Citric Acid cycle.   
In conditions where the cell does not have oxygen molecules readily available, 
such as during high intensity exercise, the systematic fermentation of pyruvate results 
in the production of lactate.  Lactate, an ionized form of lactic acid, accumulates in 
the cell during these processes due to pyruvate being converted by lactate 
dehydrogenase.  When produced at rates greater than the rates of digestion by muscle 
tissue, the lactate accumulation can result in acidic pH changes in the blood and 
tissue, leading to fatigue.   
In the aerobic pathway to ATP production, the Kreb’s cycle follows glycolysis 
by converting acetyl-CoA into citrate via the addition of oxaloacetate.  Oxaloacetate 
is a recurring product of the Kreb’s cycle and results from the reduction of malate.  
Oxaloacetate is a point of focus in this study, as the supplement being tested, 
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Benagene, is chiefly the conjugate acid of oxaloacetate, oxaloacetic acid.  
Theoretically, an increase in oxaloacetate concentrations during high intensity 
exercise would reduce lactate accumulation by allowing nicotinamide adenine 
dinucleotide, NAD+, molecules in the cytosol more opportunity to reduce pyruvate to 
acetyl-CoA.  This would prevent measures of pyruvate from being reduced to lactate 
via anaerobic fermentation.   
 During non-vigorous exercise, lactate is produced in muscle tissues and 
broken down at a similar rate, maintaining homeostasis.  When exercise is intensified, 
there is a gradual increase in muscle lactate concentrations and blood lactate 
concentrations.  The point of onset lactate accumulation is called the lactate threshold.  
The increase in lactate is largely due to both the hydrolysis of ATP and breaking 
down of carbohydrates.  If the concentration reaches levels that are not sustainable in 
the muscle during exercise, blood lactate will increase to unbearable intensity, and 
exhaustion will occur. 
 
Literature Surrounding Oxaloacetate Supplementation 
 The literature surrounding oxaloacetate is expansive.  The body of work 
surrounding oxaloacetate as a supplement, specifically, is less thorough.  The 
majority of that body of work is composed of research regarding caloric restriction 
and gene expression.  However, the studies linking oxaloacetate to muscle fatigue is 
nearly non-existent.  This is because, only recently, it was inferred that if oxaloacetate 
relates to more successful aging, then so must it engage a more efficient exercise 
metabolism.  In a study by Nogueira, Hogan and Hogan (2011), oxaloacetate 
supplementation was found to significantly increase muscle endurance in mouse 
muscle tissue.  Thus, there is some validity to the notion that oxaloacetate 
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supplementation may increase muscle endurance, though this study is one of very few 
to explore this topic. 
There have been ample studies in regard to the involvement of oxaloacetate 
with altered gene expression and increased lifespan due to calorie restriction.  Calorie 
restriction, the literal lessening of calories consumed has been directly linked to 
altering gene expression and extending the human lifespan (Dhahbi et al. 1999).  The 
three pathways identified for altering gene expression via caloric restriction include 
the activation of adenosine monophosphate kinase (AMPK), the increase in NAD+ 
inside the mitochondria, and the protection of mitochondrial DNA.   
Oxaloacetate has been shown to activate these pathways, as additional 
oxaloacetate in the cell leads to increasing NAD+ concentrations (Cash 2009).  
NAD+ has been shown to activate AMPK, which synthesizes DNA, reduces 
nucleotide cofactors, and oxidizes substrates (Raphealoff-Phail 2004).  Thus, by 
increasing oxaloacetate concentrations, the NAD+/NADH ratio can be increased, 
AMPK can be activated, calorie restriction can be mimicked, and lifespan can be 
extended.   
It should be noted that oxaloacetate supplementation has been proven to 
increase lifespan in C. elegans through the aforementioned mechanisms, as well 
(Williams, Cash, Hamadani and Diemer, 2009). Since C. elegans is a model species 
used as a reference for effects on humans, this infers that oxaloacetate 
supplementation should have similar results on humans.   
While there is little research done in regard to oxaloacetate’s role in altering 
muscle endurance, there is ample evidence suggesting that oxaloacetate may be more 
involved in the body than we know.  Based on our knowledge of intracellular 
metabolism and the balance between aerobic and anaerobic metabolism, we 
4 
hypothesize that oxaloacetate supplementation will increase muscle endurance during 
high intensity cycling.    
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Chapter 2: Methods 
Subject Recruitment  
The subjects for the study were volunteers, males’ ages 18-44 years and 45-54 
years if they were screened and deemed not at risk for hypercholesterolemia and 
impaired fasting glucose and females’ ages 18-54 years.  The subjects were allowed 
to partake in the study if they had less than two cardiovascular risk factors outlined by 
the American College of Sports Medicine.  Each subject submitted documents 
regarding medical history and were asked to complete a physical activity readiness 
questionnaire (PAR-Q).  This research project was approved by the Institutional 
Review Board for Human Subjects of the University of Southern Mississippi. 
 
Testing Phases 
The experimentation occurred in five phases, with the first being a preliminary 
familiarization session and the following four sessions being analysis during exercise.  
During the familiarization session, subjects completed an informed consent form, a 
medical questionnaire, a physical activity readiness questionnaire, measured body 
height and weight, body composition via DEXA, resting heart rate, lactate and 
oxygen uptake.  Subjects were also introduced to the preliminary stationary cycling 
protocol, which consisted of a standardizing warm up of fifteen minutes, a practice 
run of the test, and a recovery stage.   
The first experimental tests (T1) occurred within 3-7 days after participants 
completed the familiarization stage and consisted of tests to determine maximum 
oxygen uptake (VO2max) and lactate threshold.  Initial steps included measurement 
of resting heart rate, lactate levels, and oxygen uptake.  Following this, the subjects 
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completed a 10-minute warm up followed by an incremental exercise test for 
measurement of VO2max and blood lactate concentration.   
For the VO2max tests, subjects were fitted with a breathing mask connected to 
a Vyasis Vmax Encore metabolic measurement system.  The system software 
analyzed and reported all major variables, aside from lactate levels.  Lactate levels for 
this study were gathered via 5-microliter blood samples drawn from the earlobe or 
fingertip.  The cycling test began at a resistance of 100W and incrementally increased 
by 30W every three minutes until the subjects reached volitional fatigue and could no 
longer continue, as indicated by a decrease of 10 RPMs or more.  Immediately, 
resistance was reduced and a 15-minute recovery ride was completed.   
The next test (T2) occurred 3-7 days following the T1 and consisted of a 30-
minute test ride at the subjects’ established lactate threshold.  Blood lactate samples 
were taken every 4-5 minutes to ensure lactate levels remained constant.  Resistance 
was altered accordingly, to maintain lactate threshold throughout the test.  After T2 
was completed, the treatment and control groups were established.  The treatment 
group was given a 28-day supply of Benagene and the control received a placebo.  
The groups were instructed to take two 100mg pills daily with breakfast.  Subjects 
repeated tests T1 and T2, as T3 and T4 within 3-7 days after completion of the 28-day 
supplementation period.   
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Chapter 3: Results 
 
 
Six endurance-trained cyclists and triathletes completed the testing protocol (3 
Supplement, 3 placebo) (Table 1).  Group 1 consisted of the placebo and group 2 was 
established as the treatment group.  Fifteen subjects began the exercise testing 
protocol and six completed it successfully.  During the testing period, subjects were 
asked to continue their normal training regimen.  Testing included two tests, T1 and 
T3, for the determination of VO2max and lactate threshold (LaTh) (Table 2) and two 
tests, T2 and T4, for the determination of power output and HR at LaTh (LaTh 
defined as [La] of ~4 mmol/L) (Table 3) during a 30-min cycle test.   
Tests T1 and T3 results showed no change or a slight decrease in VO2max, 
which was expected due to the short duration of the study and because subjects were 
well trained. Maximal power output demonstrated an increase in Group 1 and no 
change in Group 2, which we account for as a greater familiarization to the test and 
small subject number. Power at LaTh also increased in Group 1 and Group 2, with 
Group 1 having the greater increase, which was expected due to the greater maximal 
power output.  Results in maximal heart indicated no changes. 
  
Table 1. Characteristics of subjects (n=6) 
Age (yrs) Weight (kg) Height (in) BF (%) 
31.88 ± 7.32 80.50 ± 8.36 71.31 ± 2.24 16.99 ± 5.23 
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Table 2. Results of Test for Maximal Oxygen Consumption, 
Lactate Threshold and Heart Rate Pre-Post Supplementation  
Test 
 
 
VO2max 
(ml/kg/min) 
 
Pmax (W) 
 
 
P-LaTh 
(W) 
 
HRmax 
(bpm) 
 
 Group 1    
T1 54.67 ± 14.4 340 ± 64.8 210 ± 50.9 180.7 ± 11.8 
T3 54.0 ± 11.49 390 ± 70.7 270 ± 70.7 180 ± 9.9 
 
Group 2 
   T1 49.8 ± 8.7  370 ± 42.4 260 ± 14.1 180 ± 9.9 
T3 53.17 ± 5.8 370 ± 48.9 286.7 ± 9.4 182 ± 6.2 
 Pmax = maximal power output, P-LaTh = Power at LaTh  
 
Results of tests T2 and T4 to determine power output (P-LaTh) and heart rate 
at a LaTh (HR-LaTh) of ~ 4 mmol/L are shown in Table 3.  Power output at LaTh 
improved in both groups while HR-LaTh had a slight increase in Group 1 and a slight 
decrease in Group 2.  Again, with such a low number of subjects completing the test, 
results are inconclusive.  No statistics were completed at this time due to the low 
number of subjects.   
 
Table 3. Results of 30-min Cycle Test at Lactate Threshold  
Pre-Post Supplementation  
Test  P-LaTh (W) HR-LaTh (bpm) [La] mmol/L 
 Group 1   
T2 230 ± 57.9 153.3 ± 6.24 3.87 ± 0.12 
T4 251.7 ± 77.1 155.6 ± 9.81 3.93 ± 0.12 
 
Group 2 
  T2 258.33 ± 22.5 159.3 ± 14.5 3.8 ± 0.08 
T4 265 ± 28.6 155.3 ± 8.1 4.13 ± 0.17 
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Chapter 4: Discussion 
 This study was to determine any benefits that Benagene supplementation may 
have on decreasing the accumulation of lactate and therefore increase the LaTh 
during high intensity cycling exercise.  Any changes that were expected would be 
attributed to an increased amount of Citric Acid cycle cofactors, as well an increased 
amount of free NAD+.  In the beginning of the Citric Acid cycle, oxaloacetate binds 
to citrate synthase and creates a binding site for acetyl-CoA, the pyruvate derivative 
from glycolysis.  Citrate is then formed from the mixture and the Citric Acid cycle 
continues (Williams, Fleck and Deschenes, 2012).  By increasing oxaloacetate 
concentrations, more citrate could theoretically be formed and the cycle could be 
completed at a greater rate than without supplementation due to the increased ability 
to use more fatty acids as fuel and less carbohydrates.  The decrease in carbohydrate 
use would be accompanied by a reduction in lactate production.  This alone would 
lead to greater production of energy inside the cellular mitochondria and a greater 
power output at LaTh.   
 At the end of anaerobic glycolysis, pyruvate may be reduced to lactic acid due 
to the need to regenerate NAD+ from NADH.  In the Citric Acid cycle, the step that 
forms oxaloacetate results in the formation of NADH from NAD+ molecules.  By 
increasing oxaloacetate concentrations in the mitochondria, the oxaloacetate-forming 
step in the Krebs cycle may be bypassed, resulting in a greater amount of free NAD+ 
and increasing the NAD+/NADH ratio (Cash 2009).  The increased amount of 
available NAD+ could be a reason for reduced lactate production from anaerobic 
glycolysis, as lactate is formed from pyruvate being reduced by free NADH.  
However, because we had a greater increase in maximal power and power at LaTh in 
Group 1 than Group2, and similar changes in both groups, treatment and control, in 
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power ant LaTh, it is hard to deduce if any differences in performance were observed 
due to supplementation without increasing the subject pool.   
As in any experiment involving human subjects, there is undoubtedly room 
for error.  Due to the time requirements of this study, attrition was expected, but not 
to the extent observed.  With only three subjects in each of the groups, this study was 
not able to establish any statistical power but does merit the continuation to better 
establish any possible effects.   
Possible future directions could include more in-depth repeats of this study, 
consisting of more subjects under more controlled circumstances.  Because of 
scheduling conflicts and errors mentioned, many subjects had to withdraw from the 
program causing our study to lose statistical power.  If a study such as this were to be 
conducted with 18-20 subjects, the power of the results would increase substantially 
and results could be used to better suggest any possible ergogenic effects. 
The implications of this study are of interest to the scientific community for 
two reasons, athletic gain and increasing lifespan.  If the supplementation does indeed 
increase muscle efficiency, then athletes may benefit from either reducing the use 
carbohydrates during submaximal exercise, delaying fatigue due to depletion, or 
increase the use of fatty acids at higher intensities, increasing the LaTh.  By simply 
including this compound in their dietary intake, athletes could train at higher 
intensities and achieve entirely new feats by being able to endure harsher conditions, 
for longer.   
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Chapter 5: Conclusion 
Our study has several limitations.  First, the experiments were conducted 29-
35 days after completion of the second test (T2), which made it difficult to retain 
subjects due to life events.  Second, even though all subjects were trained, not all 
were equally trained at the intensity that corresponded to LaTh and therefore exercise 
tolerance at LaTh was more difficult for some.  Finally, measuring [La] during an 
incremental VO2max test gives you an estimation of [La] at each intensity during 
each 3-min stage, usually overestimating it.  This made it difficult to determine the 
most precise power output at LaTh for T2 and T4, which required adjusting the 
intensity during the 30-min cycle test until the correct power output was established.  
This could be made more precise with at least one more testing session.      
 In summary, with a greater number of subjects, results may or may not 
indicate an ergogenic effect, but no conclusion can be made at this time. 
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Appendices 
Appendix A 
Email Announcement  
The Exercise Science program in the Department of Kinesiology is 
currently looking for trained endurance cyclist or triathletes to participate 
in an exercise study to look at the possible effects of a nutritional 
supplement, Benagene, and cycling exercise performance.  If you are 
interested refer to the requirements for participation and contact 
information below. 
 
Approximately 14-20 participants are being recruited for participation in 
this study and representation from both genders and all racial and/or 
ethnic groups is encouraged. 
 
Requirements for participation include: 
• Males 18 to 44 and females 18-55 years of age 
 
• Males between 45-54 years of age will be accepted with proof of 
screening for high cholesterol and diabetes 
 
• Involved in regular aerobic exercise training for the past 6-months 
at a minimum of 30 minutes per day, 4 days per week  
 
• Must have a Body Mass Index < 30 or body fat percentage < 25%. 
 
• Must be apparently healthy with no indication of risk factors 
indicated by Health History Questionnaire 
 
• Not taking any medications that might impact exercise metabolism 
 
If you meet the previously listed requirements and are interested in 
getting more information please contact one of the following individuals: 
Wilson Simmons– Wilson.simmons@eagles.usm.edu  
Dr. Joseph Boyd – Joseph.Boyd@usm.edu 
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Appendix B 
Recruitment Poster 
- WANTED – 
RESEARCH SUBJECTS FOR A STUDY 
INVESTIGATING THE EFFECTS OF 
BENAGENE SUPPLEMENTATION ON 
HIGH INTENSITY CYCING EXERCISE  
 
Approximately 14-20 participants are being recruited for participation in 
this study and representation from both genders and all racial and/or 
ethnic groups is encouraged. 
 
Requirements for participation include: 
• Males 18 to 44 and females 18-55 years of age 
 
• Males between 45-54 years of age will be accepted with proof of 
screening for high cholesterol and diabetes 
 
• Involved in regular aerobic exercise training for the past 6-months 
at a minimum of 30 minutes per day, 4 days per week  
 
• Must have a Body Mass Index < 30 or body fat percentage < 25%. 
 
• Must be apparently healthy with no indication of risk factors 
indicated by Health History Questionnaire. 
 
• Not taking any medications that might impact exercise metabolism 
 
If you meet the following requirement and are interested in getting more 
information please contact any of the following individuals: 
Wilson Simmons– Wilson.simmons@eagles.usm.edu  
Dr. Joseph Boyd – Joseph.Boyd@usm.edu 
Dr. Michael Webster – Michael.Webster@usm.edu 
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Appendix C 
 
University of Southern Mississippi 
Laboratory of Applied Physiology 
Medical History Questionnaire 
 
Directions.  The purpose of this questionnaire is to enable the staff of the Laboratory of Applied 
Physiology to evaluate your health and fitness status.  Please answer the following questions to the best 
of your knowledge.  All information given is CONFIDENTIAL as described in the Informed 
Consent Statement. 
  
Name:         Date of Birth   
  
Name of your Physician:          
 
MEDICAL HISTORY 
Do you have or have you ever had any of the following conditions? (Please write the date when you 
had the condition in blank). 
 
____ Heart murmur, clicks, or other cardiac findings ____ Asthma/breathing difficulty  
____ Frequent extra, skipped, or rapid heartbeats   ____ Bronchitis/Chest Cold 
____ Chest Pain (with or without exertion)  ____ Melanoma/Suspected skin Lesions 
____ High cholesterol     ____ Stroke or Blood Clots 
____ Diagnosed high blood pressure   ____ Emphysema/lung disease 
____ Heart attack or any cardiac surgery   ____ Epilepsy/seizures 
____ Leg cramps (during exercise)   ____ Rheumatic fever    
____ Varicose veins     ____ Ulcers or digestive disorders 
____ Frequent dizziness/fainting   ____ Pneumonia 
____ Muscle or joint problems    ____ Anemia 
____ High blood sugar/diabetes    ____ Liver (hepatic) or kidney (renal) disease 
____ Thyroid Disease     ____ Autoimmune disease 
____ Low testosterone/hypogonadism   ____ Nerve disease 
____ Glaucoma     ____ Psychological Disorders 
____ Chronic swollen ankles    ____ Currently Pregnant 
 
 
To the best of my ability, I will take appropriate measures to prevent my pregnancy while I am a 
participant in the study.           YES     NO 
 
Do you have or have you been diagnosed with any other medical condition not listed.  YES    NO 
If yes please list: 
______________________________________________________________________________               
Please provide any additional comments/explanations of your current or past medical history that you 
feel might impact/influence your ability to participate in this study. 
  
            
            
Please list any recent surgery that you feel might impact/influence your ability to participate in this 
study.  (i.e., type, dates etc.).  
 
            
            
List all prescription/non-prescription medications and nutritional supplements you have taken in the 
last 3 months. 
                        
Do you know of any medical problem that might make it dangerous or unwise for you to participate in 
this study?   YES     NO 
If yes, please explain (use back side of this page if necessary) 
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Has your response to any of the above questions changed since the last session in the laboratory?    
YES     NO 
 
If yes, please explain:               
            
 
Initials   Date      
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Appendix E 
Informed Consent Statement 
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